Is there a role for assessing measurable/minimal residual disease (MRD) in multiple myeloma at this time?

Topics: Hematologic Malignancies • Medical Oncology • Myeloma • Hematology

Would MRD assessments affect your clinical decision making for MM patients outside of a clinical trial?

Answer from: Medical Oncologist at Community Practice

MRD assessment in myeloma is challenging. The EuroFlow standard and Adaptive ClonoSEQ technologies seem to be winning out for the moment, but the Mayo Clinic mass spectrometry peripheral blood assay may be the next generation. The advantage of the flow-cytometry based assay is that it in...

Comments

Medical Oncologist at Yale School of Medicine
Based on IFM 2009 study, following ASCT, and after...

Related Questions